|
|
News Breaks | | | | September 10, 2012 | | 07:45 EDT |  | DRTX | Durata Therapeutics announces data from dalbavancin study
Durata Therapeutics announced data from an in vitro study and surveillance results of its lead product candidate, dalbavancin, currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections. The data, presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, demonstrate the potency of dalbavancin against numerous significant bacterial isolates in the United States and Europe. | |
|
News For DRTX From The Last 14 Days Check below for free stories on DRTX the last two weeks. |
|
|
| May 9, 2013 | | 07:24 EDT |  | DRTX | Durata Therapeutics reports Q1 EPS (86c), consensus (66c)
 Subscribe for More Information | |
|
|
|
|
|
|
